Open AccessDeclining adherence is a more likely explanation than frailty of the apparent decline in efficacy in the CAPRISA 004 trial
Author(s) -
Anneke Grobler,
Salim S. Abdool Karim
Publication year - 2012
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e328355ce08
Subject(s) - confidence interval , placebo , medicine , population , microbicide , demography , hazard ratio , proportional hazards model , immunology , human immunodeficiency virus (hiv) , alternative medicine , environmental health , pathology , sociology
O’Hagan et al. [1] offer an alternate explanation for the apparent decline in efficacy over time in vaccine and microbicide trials. They propose that the decline in efficacy observed could also be explained by selection bias due to heterogeneity in infection risk. As those at highest risk are infected more in the placebo arm than in the active arm, it leads to differences in the composition of the study population in the two study arms, a phenomenon called frailty in statistics [1].
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom